BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 15287081)

  • 1. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials.
    Royston P; Sauerbrei W
    Stat Med; 2004 Aug; 23(16):2509-25. PubMed ID: 15287081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of treatment effects in subsets of patients in clinical trials.
    Bonetti M; Gelber RD
    Biostatistics; 2004 Jul; 5(3):465-81. PubMed ID: 15208206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empirical study of the dependence of the results of multivariable flexible survival analyses on model selection strategy.
    Binquet C; Abrahamowicz M; Mahboubi A; Jooste V; Faivre J; Bonithon-Kopp C; Quantin C
    Stat Med; 2008 Dec; 27(30):6470-88. PubMed ID: 18837067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
    Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
    Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of multivariable fractional polynomial models with selection of variables and transformations: a bootstrap investigation.
    Royston P; Sauerbrei W
    Stat Med; 2003 Feb; 22(4):639-59. PubMed ID: 12590419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of cumulative incidence function under the proportional hazards model.
    Cheng SC; Fine JP; Wei LJ
    Biometrics; 1998 Mar; 54(1):219-28. PubMed ID: 9544517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
    Johansen J; Overgaard J; Overgaard M
    Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in clinical cancer trials.
    Estey E
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2591-3. PubMed ID: 9815662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A parametric model for long-term follow-up data from phase III breast cancer clinical trials.
    Jeong JH; Jung SH; Wieand S
    Stat Med; 2003 Feb; 22(3):339-52. PubMed ID: 12529867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of smoothing methods to evaluate treatment-prognostic factor interactions in breast cancer data.
    Jeong JH; Costantino JP
    Cancer Invest; 2006; 24(3):288-93. PubMed ID: 16809157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
    Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
    Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size calculations for the two-sample problem using the multiplicative intensity model.
    Bernardo MV; Harrington DP
    Stat Med; 2001 Feb; 20(4):557-79. PubMed ID: 11223901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
    Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
    Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.